Search

Author/Creator Janni, W.

13. Ribociclib + letrozole for first-line treatment of HR+, HER2− ABC: efficacy, safety, and pharmacokinetics. (December 2016)

Authors:
André, F.; Stemmer, S.M.; Hortobagyi, G.N.; Burris, H.A.; Paluch-Shimon, S.; Campone, M.; Villanueva, C.; Chan, A.; Wist, E.; Marschner, N.; Bachelot, T.; Blau, S.; Janni, W.; Verma, S.; Conte, P.; Dhuria, S.; Yang, S.; Stegert, M.; Germa, C.; Arteaga, C.L.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S7
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer. (2nd July 2016)

Authors:
Wuerstlein, R.; Sotlar, K.; Gluz, O.; Otremba, B.; von Schumann, R.; Witzel, I.; Schindlbeck, C.; Janni, W.; Schem, C.; Bauerfeind, I.; Hasmueller, S.; Tesch, H.; Paulenz, A.; Ghali, N.; Orujov, E.; Kates, R. E.; Cowens, W.; Hornberger, J.; Pelz, E.; Harbeck, N.
Journal:
Current medical research and opinion
Issue:
Volume 32:Number 7(2016:Jul.)
Page Start:
1217
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗